Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
|Videos|June 14, 2021
The Current and Emerging Actinic Keratosis Treatment Landscape
Author(s)Morgan Petronelli
In this video interview, Ted Lain, MD, discusses the causes and effects of actinic keratosis, as well as the unmet needs, how to diagnose, and what treatments are currently available.
Advertisement
Advertisement
Related to this article
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
The Scariest Skin Care Trends Haunting Patients This Halloween
3
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
4
Improving Early Identification and Escalation of HS
5